Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration. The purpose of the new study was to evaluate higher doses of GAL-021 to determine an appropriate dose range for future studies, including an upcoming Phase I proof-of-concept study utilizing conditions simulating post-operative patients who have impaired respiration.    

The new study evaluated a single dose of GAL-021 in 18 healthy volunteers using higher doses of GAL-021 than the previous Phase I trial. The placebo-controlled, double-blind, crossover study confirmed the drug's positive effects, including improved minute ventilation (a capacity measure of air supplied to the lungs) and decreased end-tidal carbon dioxide levels (a measure of the effectiveness of alveolar gas exchange), demonstrating a clear dose response on these respiratory parameters. Side effects of the drug were generally mild to moderate. At the highest dose in some subjects, the improved lung ventilation was sufficient to increase in minute ventilation by more than 50% and in parallel lower CO2 levels more than 25%.

"This study confirmed our previous Phase I findings and establishes a clear dose range for future studies," said James F. McLeod, M.D., Galleon's senior vice president, clinical research and development, and chief medical officer. "We identified a maximum tolerated dose of the drug in healthy volunteers which produced hyperventilation and decreased CO2 levels, and can now proceed with plans to evaluate the effects of GAL-021 in those with opioid-induced respiratory compromise. Our goal will be to demonstrate that GAL-021 can reduce or prevent respiratory depression associated with opioid use following surgery or other medical procedures."

GAL-021 is a proprietary small molecule delivered by intravenous administration to treat or prevent acute respiratory insufficiency in surgical and critical-care patients following the use of anesthetic, analgesic and sedative drugs individually or in combination. Galleon estimates there are 23 million surgeries performed every year which require anesthesia and pain control, with an estimated 35-40% of those being done in patients at higher risk for respiratory depression.

Source:

Galleon Pharmaceuticals       

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study suggests beta-blockers may elevate depression symptoms in post-MI patients